Tvardi Therapeutics, Inc. - Asset Resilience Ratio
Tvardi Therapeutics, Inc. (TVRD) has an Asset Resilience Ratio of 38.55% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Tvardi Therapeutics, Inc. carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2022)
This chart shows how Tvardi Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. See Tvardi Therapeutics, Inc. net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Tvardi Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Tvardi Therapeutics, Inc..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $15.04 Million | 38.55% |
| Total Liquid Assets | $15.04 Million | 38.55% |
Asset Resilience Insights
- Very High Liquidity: Tvardi Therapeutics, Inc. maintains exceptional liquid asset reserves at 38.55% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Tvardi Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Tvardi Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Tvardi Therapeutics, Inc. (2020–2022)
The table below shows the annual Asset Resilience Ratio data for Tvardi Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 49.34% | $22.25 Million | $45.10 Million | -12.83pp |
| 2021-12-31 | 62.16% | $153.58 Million | $247.06 Million | +7.13pp |
| 2020-12-31 | 55.04% | $149.24 Million | $271.16 Million | -- |
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on … Read more